KRAS and cancer: Notably, pembrolizumab and nivolumab, previously discussed as monoclonal antibodies, overlap with this category, as they release the brakes on T cells and are very effective against oncogene-driven cancers that have mutations in genes like KRAS and EGFR [236,237].